Antipsychotic Medications for Bipolar Disorder: Uses and Monitoring
Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Antipsychotic medications have established roles in bipolar disorder, including the treatment of acute mania, selected bipolar depressive episodes, and prevention of recurrence in some patients. Which medicine is appropriate depends on the phase of illness, diagnostic history, previous response, physical health, and preferences. The class name does not imply that a person taking one experiences hallucinations or delusions: antipsychotics have bipolar-specific effects even when psychosis is absent. CANMAT NIMH
This guide explains their differing clinical indications, evidence-based choices, side effects, monitoring schedule, and practical safety decisions. General treatment options are covered in Medications for Bipolar Disorder: Mood Stabilizers and Other Options and the overall clinical pathway in Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care. Medication decisions require a clinician who can assess episodes and functioning over time; a screening result or an isolated change in mood cannot determine treatment.
For additional clinical context, see Valproate for Bipolar Disorder: Uses, Risks, and Reproductive Safety.
What are antipsychotics and how do they help bipolar disorder?
Antipsychotics include older first-generation agents and newer second-generation, sometimes called atypical, medications. Most frequently used bipolar treatments in this class affect dopamine and serotonin neurotransmission, though their receptor actions vary substantially. In acute mania, effective agents may reduce excessive activation, agitation, severe sleep disruption, and associated psychotic symptoms. Some agents also reduce bipolar depressive symptoms or recurrent episodes. Neurochemical similarity does not establish clinical interchangeability: phase-specific clinical trials and safety evidence govern treatment decisions. CANMAT DRUG
Bipolar I disorder involves a history of mania; bipolar II disorder involves hypomania and major depression without a history of full mania. Hypomania is clinically distinct from mania, and bipolar II is not simply a milder version of bipolar I. Mania can produce severe impairment, hospitalization, or psychosis, whereas bipolar depression brings a different pattern of symptoms and treatment needs. Clinicians must establish the current episode, previous episodes, mixed features, and other possible explanations before prescribing. VA NIMH
Antipsychotics for acute mania
Second-generation antipsychotics with substantial evidence for acute mania include quetiapine, risperidone, aripiprazole, asenapine, and cariprazine. The 2023 CANMAT/ISBD summary also lists paliperidone at effective therapeutic doses among first-line monotherapy options for acute bipolar I mania. Olanzapine and ziprasidone appear among additional evidence-based choices, with guideline placement reflecting tolerability as well as efficacy. These agents can reduce manic symptoms but differ in metabolic, movement, cardiovascular, and sedating effects. CANMAT VA
Depending on episode severity and previous treatment, an antipsychotic may be used alone or alongside lithium or divalproex. Combination treatment may be justified during severe mania, especially when rapid symptom stabilization is essential, but it adds monitoring and adverse-effect complexity. Severe insomnia with behavioral disorganization, dehydration, risky judgment, psychosis, inability to meet basic needs, or danger to self or others calls for urgent assessment. The specialized management pathway is explained in Treatment for Acute Mania: Safety, Medication, and Specialist Care. CANMAT NICE
Some first-generation drugs such as haloperidol also have antimanic efficacy but may bring greater risk of particular movement disorders. Emergency use and maintenance use involve different goals, settings, and formulations. Temporary calming or sedation is not itself proof that core mania has resolved; clinicians examine sleep, speech, thought processes, activity, judgment, and restored functioning over the treatment course. VA DRUG
Antipsychotics for bipolar depression
The evidence base changes markedly for bipolar depression. Quetiapine is a guideline-supported first-line treatment for bipolar I depression and the only first-line option specified for acute bipolar II depression in the 2023 CANMAT/ISBD hierarchy. Lurasidone is supported for bipolar I depression, as monotherapy or as an adjunct to lithium or valproate in adults. Cariprazine has adult bipolar I depression evidence and was upgraded to a first-line recommendation. Lumateperone has clinical trial evidence and a U.S. indication for adult depressive episodes associated with bipolar I and bipolar II disorders. CANMAT LURA CARI CAP
The fixed olanzapine–fluoxetine combination also has evidence for acute bipolar I depression. Its potential for weight gain and metabolic disturbances is an important reason to consider the comparative harms and benefits before selection. Evidence for the fixed combination does not establish that either component alone is therapeutically equivalent for this indication. See the phase-specific analysis in Bipolar Depression Treatment: Medications, Therapy, and Evidence. OFC CANMAT
Many medicines effective in mania cannot be assumed effective in bipolar depression. For example, aripiprazole monotherapy is not recommended for acute bipolar I depression by CANMAT/ISBD, despite its established antimanic and relapse-prevention roles. Lurasidone’s U.S. labeling states that its effectiveness in bipolar mania has not been established. These distinctions make a universal ranking of antipsychotics for bipolar disorder clinically misleading. CANMAT LURA
Antipsychotic medications for maintenance treatment
Long-term treatment aims to prevent future episodes and preserve functioning. CANMAT/ISBD identifies quetiapine, asenapine, and aripiprazole among guideline-supported bipolar I maintenance options, with some combinations of these medicines and lithium or divalproex. Other antipsychotics have narrower evidence or later-line roles. The same medicine may protect against recurrence of mania more reliably than recurrence of depression. Clinicians evaluate the patient’s predominant previous episode pattern, response to acute treatment, and tolerability. CANMAT
Continuing an antipsychotic after stabilization from mania can reduce recurrence for some patients, particularly when it was part of an effective acute-phase combination. The expected benefit over extended periods must be reevaluated against ongoing metabolic, neurologic, and functional burden. A long-term plan includes relapse warning signs, symptom monitoring, collaborative reviews, and psychotherapy or practical support where appropriate. For this treatment phase see Bipolar Maintenance Treatment: Preventing Relapse Over Time. CANMAT NICE
Long-acting injectable formulations
Certain extended-release aripiprazole injections have a U.S. maintenance indication for bipolar I disorder in adults, and long-acting risperidone has relevant maintenance evidence. These formulations may support consistent delivery when daily adherence is difficult or a patient prefers an injection schedule. Each product has its own indication, administration interval, initiation requirements, and follow-up rules. Injectable treatment does not eliminate movement, metabolic, cardiovascular, or effectiveness monitoring. ARILAI CANMAT
How individual antipsychotic medications differ
Quetiapine
Quetiapine has evidence across acute mania, bipolar depression, and selected maintenance regimens, which is valuable when both elevated and depressed mood episodes are clinically important. Its burdens can include sleepiness, dizziness, orthostatic hypotension, appetite changes, weight gain, and metabolic abnormalities. The physician monitors daytime alertness and functioning as well as symptom scores. Better sleep alone cannot demonstrate full remission of a bipolar episode. CANMAT NICE
Aripiprazole
Aripiprazole is used for acute mania and maintenance, including certain injectable preparations. Akathisia, or an intense inner feeling of restlessness, is a meaningful adverse effect and can be mistaken for anxiety or worsening agitation. It should not be assumed to treat acute bipolar depression as monotherapy merely because it controls mania. Maintenance studies include individuals stabilized following manic or mixed episodes, which matters when applying their conclusions to depressive relapse. ARI CANMAT
Risperidone and paliperidone
Risperidone is supported in mania and particular maintenance strategies. Paliperidone has evidence in acute mania at specified effective doses and certain longer-term scenarios. Drug-induced stiffness or tremor, prolactin effects, and changes in glucose and weight require attention. Menstrual disruption, breast discharge, changes in sexual functioning, and subjective movement restlessness may be clinically significant even if patients do not volunteer them initially. The prescribing information for each specific formulation controls its approved indication. CANMAT NICE
Olanzapine and olanzapine–fluoxetine
Olanzapine is effective in mania; the combination with fluoxetine has an indication for acute bipolar I depression. Olanzapine can substantially increase appetite and weight and worsen glucose or lipid parameters in some patients, so its metabolic burden often shapes the decision even when it is effective. A 2024 bipolar-disorder network meta-analysis found important between-drug differences in several metabolic outcomes, including unfavorable lipid results for olanzapine. Individual risk is not predicted perfectly by average trial results. OFC KONG
Lurasidone
Lurasidone is a bipolar I depression medicine, not an established treatment for bipolar mania. It must be taken with food containing at least 350 calories because absorption changes substantially with food. Nausea, akathisia, other movement symptoms, and medication interactions can be consequential. CYP3A4 inhibitors or inducers and hepatic or renal impairment require specific prescribing review. Its average weight-gain profile may compare favorably with some drugs, but blood sugar, lipids, and weight must still be followed. LURA KONG
Cariprazine
Cariprazine is supported for adult bipolar I mania and bipolar I depression, with different treatment approaches for these phases. Akathisia, restlessness, movement symptoms, and nausea are important tolerability issues. Long-lasting active metabolites mean that some medication effects or side effects may take time to reflect a change in exposure. Drug interactions and delayed tolerability changes need clinician supervision. Specific pediatric indications differ from adult depressive indications. CARI CANMAT
Lumateperone
Lumateperone has a U.S. indication for adult bipolar I and bipolar II depressive episodes, as monotherapy or adjunctive to lithium or valproate. Its adult depression evidence must not be generalized to acute mania, established recurrence prevention, or pediatric patients. Sedation, dizziness, nausea, and dry mouth may occur; interactions and liver disease can influence treatment. The current U.S. label should be consulted for product-specific precautions and patient counseling. CAP CANMAT
Asenapine, ziprasidone, and other agents
Asenapine appears in antimanic and maintenance treatment guidelines, whereas ziprasidone has specific antimanic and selected adjunctive maintenance roles. QT-interval risk and co-prescribed QT-prolonging drugs can influence selection of ziprasidone and ECG assessment. Specialist options such as clozapine may be considered in rare treatment-resistant circumstances and involve substantially different safety surveillance. Licensing differs by product, country, age, and indication. CANMAT NICE
What determines medication selection?
Prescribers consider the current mood phase, prior manic and depressive episodes, any psychotic or mixed features, suicidal or functional risk, response to previous drugs, medical illness, co-occurring conditions, and personal preferences. The clinician reviews medications, substance use, sleep patterns, and factors affecting medication exposure or adherence. A patient with metabolic risk may reasonably weigh weight-gain liability heavily; someone with marked restlessness may prioritize akathisia risk; cardiovascular disease may call for ECG review. NICE VA
Drug choice also depends on cost, access to follow-up, whether daily or injectable administration is suitable, the impact of sedation on work or caregiving, and the patient’s experience of previous treatment. The plan should specify what improvement is expected, which side effects are acceptable, when to reassess, and how to contact the team if safety concerns emerge. The decision is a documented therapeutic trial rather than a one-time prescription without follow-up. NICE
Antipsychotic monitoring: baseline and follow-up schedule
Monitoring is integral to safe antipsychotic use. Before treatment, NICE CG185 recommends recording weight or body mass index, pulse, blood pressure, fasting blood glucose or HbA1c, and a lipid profile. An ECG should be offered where indicated by product labeling or cardiovascular risk, relevant family history, arrhythmia, prior collapse, or inpatient admission. The initial assessment also records preexisting movement symptoms, other medicines, clinical targets, and medical conditions relevant to prescribing. NICE
Before the first dose
The baseline review should cover weight trajectory, diabetes and lipid risk, blood pressure and heart disease, exercise and diet context, abnormal movements, previous drug reactions, current medicines, and kidney or liver conditions as clinically relevant. Pregnancy plans, sleep apnea, seizures, and substance use may affect the decision. Baseline values allow later changes to be identified and investigated rather than attributed to medication without evidence. NICE CANMAT
During dose changes and the first 12 weeks
NICE CG185 recommends checking pulse and blood pressure after each dose change, measuring weight or BMI weekly for the first six weeks and at week 12, and repeating fasting glucose or HbA1c and lipids at week 12. Clinicians regularly document symptom response, side effects, movement disorders, functioning, and adherence. A person with rapid weight change or a relevant medical condition may need earlier or more frequent tests. This is a guideline schedule, not a substitute for drug-specific labeling or individualized U.S. care. NICE
Ongoing monitoring
Long-term follow-up includes weight and cardiometabolic indicators, movement effects, subjective experience, mood symptoms, sleep, and real-world functioning. NICE recommends at least an annual general physical-health review for people with bipolar disorder; antipsychotic treatment often calls for additional monitoring based on risk. The specialist team should maintain responsibility for monitoring efficacy and tolerability for at least the first 12 months or until the condition stabilizes, whichever is longer, with explicit shared-care arrangements afterward. NICE
Abnormal lab results need follow-up, possible repeat testing, and appropriate medical management. A clinically effective antipsychotic may still require reconsideration if adverse effects become serious; normal labs do not by themselves prove that episodes are well controlled. Monitoring addresses symptom benefit and physical safety as separate, complementary outcomes. NICE KONG
Weight gain, glucose, cholesterol, and cardiovascular health
Antipsychotics can affect appetite, body weight, insulin regulation, glucose, and blood lipids. Their effects differ by drug and person, and cardiometabolic changes may occur without obvious weight gain. A 2024 network meta-analysis examined 41 trial publications involving 11,678 bipolar-disorder trial participants and reported important between-agent differences in metabolic parameters. Rankings from such indirect comparisons should be interpreted cautiously because study duration, populations, and measured outcomes vary. KONG
Weight gain or abnormal metabolic testing warrants clinical review and practical support, not blame. The response may include repeat testing, collaborative cardiovascular risk reduction, treatment of diabetes or dyslipidemia, consideration of a lower-risk medication, or other clinician-directed strategies. Individuals with preexisting metabolic disease can still benefit from bipolar treatment while receiving coordinated health care and appropriately frequent monitoring. NICE KONG
Movement side effects and what they feel like
Akathisia can cause pacing, inability to remain seated, or an intense inner urge to move; it is sometimes confused with anxiety or renewed manic agitation. Drug-induced parkinsonism may produce tremor, stiffness, or slowness, while dystonia involves involuntary sustained muscle contractions and may need urgent assessment. Clinicians should ask about subjective distress as well as examine movements after initiation and dose adjustments. NICE DRUG
Tardive dyskinesia is characterized by involuntary repetitive movements, often of the mouth, tongue, face, or limbs, associated with exposure to dopamine receptor-blocking drugs. It can persist after stopping treatment. A regular movement examination and early review of new symptoms are important; people should not abruptly stop medication on their own because of suspected tardive dyskinesia. DRUG NICE
Sedation, cardiac effects, prolactin, and rare emergencies
Sedation can impair driving, work, concentration, and safe mobility; postural dizziness may contribute to falls. Some antipsychotics can prolong the QT interval, especially with interacting drugs or electrolyte abnormalities. A risk-based ECG and prescribing review may be appropriate. Prolactin elevation may cause menstrual irregularity, sexual dysfunction, breast symptoms, or other hormonal concerns. Constipation and other anticholinergic effects vary by drug and can be clinically important. NICE CHILD
Rare serious reactions include neuroleptic malignant syndrome, in which fever, severe muscle stiffness, autonomic disturbance, and changes in consciousness may occur. Sudden collapse, serious palpitations, new severe rigidity with fever, or profound confusion warrant urgent medical care. Marked thirst, frequent urination, vomiting, and altered consciousness may also signal a dangerous glucose-related complication. Patients and families should seek immediate evaluation rather than await a routine visit. DRUG NICE
Suicide-related safety and urgent clinical assessment
Bipolar depression can involve suicidal thoughts, and severe mania or mixed states can impair judgment. Clinicians monitor new or worsening depression, agitation, activation, impulsivity, or suicidal thinking after medication changes and throughout treatment. Some antipsychotic product labels contain warnings associated with antidepressant-related suicidal thoughts and behaviors in young people; the exact labeled risk depends on the individual product and patient population. CAP LURA NIMH
Immediate intent to harm oneself, a specific plan with access to means, psychosis with loss of safety, inability to meet basic needs, or severe mania with imminent risk requires emergency evaluation. In the United States, 911 is for immediate danger and 988 offers suicide and crisis support. Relatives and supporters can help the person access care and share observations with clinicians, respecting safety and consent whenever possible.
Combining antipsychotics with other medications
During severe mania, lithium or divalproex may be combined with a suitable antipsychotic. These combinations sometimes improve control of acute symptoms or support maintenance but can increase the burden of adverse effects and interactions. Lithium has drug-level, kidney, thyroid, and related monitoring needs; valproate has hematologic, hepatic, and important reproductive safety requirements. Antipsychotic metabolic tests are not a replacement for those additional safeguards. CANMAT NICE
Routine treatment with two antipsychotics is generally discouraged by NICE except for short transitions such as a planned cross-taper. As-needed prescriptions also need review so they do not inadvertently increase total exposure beyond intended limits. Antidepressant use has its own bipolar-specific evidence and concerns about switching into mania or worsening mixed features; that topic is developed in Antidepressants in Bipolar Disorder: Mood Switching Risk and Clinical Guidance. NICE CANMAT
Antipsychotics in children, older adults, and pregnancy
Children and adolescents
Bipolar diagnosis and pharmacologic treatment in children require specialist, developmentally appropriate assessment. Some antipsychotics have United States indications for defined pediatric age ranges and specific bipolar phases; adult evidence cannot be transferred automatically. Children may experience especially rapid weight and metabolic changes. Height and weight plotted on growth charts, blood pressure, glucose, lipids, movement symptoms, and prolactin when appropriate require careful surveillance and family involvement. CHILD LURA CARI
Older adults
Older adults may be more susceptible to dizziness, falls, sedation, medication interactions, and other adverse effects, particularly with physical comorbidity or cognitive change. FDA boxed warnings highlight an increased risk of death when antipsychotics are used in older patients with dementia-related psychosis; the warning does not mean that bipolar disorder itself is dementia-related psychosis. Prescribers should reassess benefit, medical risks, and function at appropriate intervals. CAP CANMAT
Pregnancy and postpartum
Pregnancy planning calls for coordinated psychiatric and obstetric care. The balance includes relapse risk without treatment, severity of past episodes, evidence specific to the drug, and possible fetal or neonatal effects. ACOG advises against withholding or discontinuing mental health medication solely because of pregnancy or lactation status; decisions should be individualized. Some antipsychotic labels warn of neonatal extrapyramidal or withdrawal symptoms after exposure late in pregnancy. Breastfeeding safety also depends on the specific medicine and infant circumstances. ACOG CAP
Sudden self-directed stopping during pregnancy or postpartum can increase risk of destabilization. The care team should discuss reproductive plans early, especially when lithium or valproate is also part of the regimen, because those medications have their own distinct reproductive and monitoring considerations. ACOG CANMAT
What if treatment does not work or adverse effects are difficult?
Before determining that a medication has failed, clinicians examine the diagnosis, current phase, adequacy of exposure, treatment duration, adherence, interactions, co-occurring conditions, and whether adverse effects are being mistaken for recurrent symptoms. A medication helpful in mania may be ineffective for depression. Worsening restlessness should prompt consideration of akathisia rather than automatically being labeled relapse. CANMAT VA
Troubling weight gain, sedation, sexual effects, or abnormal laboratory results warrant discussion with the prescribing clinician. An individualized response might involve medical treatment of adverse effects, changing other interacting medicines, a supervised switch, or modification of the longer-term plan. Discontinuing abruptly can increase recurrence risk; NICE advises reducing an antipsychotic gradually over at least four weeks when stopping, with clinical judgment for the circumstances. NICE NIMH
Practical questions to bring to an appointment
A useful medication review asks which phase of bipolar disorder is being treated; what improvement should occur and when; why this antipsychotic was selected; which side effects are most important; when weight, blood pressure, glucose, and lipids will be checked; and what symptoms warrant earlier contact. Record the specific formulation, start date, recent changes, sleep and mood trends, movement symptoms, and follow-up plan. Shared decisions are easier when goals and concerns are explicit. NICE
Family members and other trusted supporters may help identify major changes in sleep, judgment, activity, or behavior, with appropriate consent. Consistent routines, psychoeducation, psychotherapy, and a relapse-prevention plan can complement medication without replacing evidence-based acute care. NIMH CANMAT
Common misconceptions
Does taking an antipsychotic mean a person has psychosis?
No. Multiple antipsychotics have established indications for mania, bipolar depression, or recurrence prevention even when hallucinations and delusions have never occurred. The prescribing clinician should specify the treatment goal. NIMH
Do all antipsychotics treat bipolar depression?
No. Clinical trial evidence differs by drug and phase. Quetiapine, lurasidone, cariprazine, lumateperone, and the olanzapine–fluoxetine combination have relevant evidence in defined populations; aripiprazole alone is not recommended for acute bipolar I depression. CANMAT CAP
Does mood improvement mean monitoring can stop?
No. Metabolic and neurologic risks may evolve during continued treatment and require follow-up even while mood is stable. Treatment response and physical safety are separate priorities. NICE
Frequently asked questions
Which antipsychotic is best for bipolar disorder?
There is no universal best agent. The right decision depends on mania, depression, or maintenance as the immediate goal, plus prior response, co-occurring illnesses, interactions, physical risk, and preferences. A clinician compares phase-specific benefits and harms with the patient. CANMAT
How quickly do antipsychotics work for mania?
Some calming effects can appear relatively early, while meaningful improvement in core mania is measured over the treatment course. Severe agitation, psychosis, unsafe judgment, or prolonged sleeplessness calls for prompt assessment even after medication has been started. DRUG VA
Can an antipsychotic be used without lithium?
Yes, for selected indications an antipsychotic alone is evidence-based. Other situations require or favor combination treatment. The response during the acute episode and the longer-term relapse plan are assessed separately. CANMAT
What is the usual monitoring schedule?
Baseline measures include weight or BMI, blood pressure, glucose or HbA1c, and lipids. NICE recommends weekly weight measurements for six weeks, another measurement at 12 weeks, and glucose and lipid tests at 12 weeks, followed by ongoing individualized surveillance. Product-specific and medical risk factors can require more testing. NICE
Can antipsychotic medication cause weight gain even with healthy habits?
Yes. Medication exposure can affect appetite and metabolism, with responses varying considerably. Any important change deserves clinical review and support without assigning blame. KONG
Is it safe to stop once symptoms improve?
Stopping medication without a plan can lead to recurrence. Discuss missed doses and discontinuation with the prescriber because formulations, half-lives, interaction risks, and tapering requirements differ. NICE recommends supervised gradual reduction if an antipsychotic is discontinued. NICE NIMH
Is antipsychotic treatment safe in pregnancy?
There is no single answer for the entire class. The decision depends on the specific drug, severity of the bipolar history, pregnancy stage, and risks of untreated episodes, and it should be reviewed jointly by obstetric and mental-health clinicians. ACOG
Related Articles
References
American College of Obstetricians and Gynecologists. (2023). Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum. Clinical Practice Guideline No. 5. ACOG
DailyMed. Aripiprazole oral tablets. U.S. prescribing information, including bipolar I maintenance studies. ARI
DailyMed. Aripiprazole extended-release injection (Abilify Asimtufii). U.S. prescribing information. ARILAI
DailyMed. Cariprazine (Vraylar). U.S. prescribing information. CARI
DailyMed. Lumateperone (Caplyta). U.S. prescribing information, revised 2026. CAP
DailyMed. Lurasidone hydrochloride. U.S. prescribing information, updated 2026. LURA
DailyMed. Olanzapine and fluoxetine. U.S. prescribing information. OFC
Keramatian, K., et al. (2023). The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence. Focus. DOI: 10.1176/appi.focus.20230009. CANMAT
Kong, L., et al. (2024). Effect of antipsychotics and mood stabilisers on metabolism in bipolar disorder: A network meta-analysis of randomised-controlled trials. eClinicalMedicine, 71, 102581. DOI: 10.1016/j.eclinm.2024.102581. KONG
National Institute for Health and Care Excellence. (2014; updated through 2025). Bipolar disorder: assessment and management (CG185). NICE
National Institute for Health and Care Excellence. (2015). Monitoring for side effects of antipsychotic medication in children and young people (QS102, statement 6). CHILD
National Institute of Mental Health. Bipolar Disorder. NIMH
National Institute of Mental Health. Mental Health Medications. DRUG
U.S. Department of Veterans Affairs and Department of Defense. (2023). Management of Bipolar Disorder: Clinical Practice Guideline. VA